SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones

NEXT STORY
Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer
PREV STORY
Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Avadel Pharmaceuticals to Report First Quarter 2017 Results

DUBLIN, Ireland, April 17, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced it ...

author_avatar
NASDAQ Market News

Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update

-   Expanding Controlled IL-12 platform to explore additional tumor types -   Cash runway extended ...

author_avatar
NASDAQ Market News

Principal Investigator Dr. James Gulley to Provide Presentation Entitled “Therapeutic Vaccines in Prostate Cancer” at the ESMO 2017 Congress

MADRID, September 11, 2017 - This morning at the European Society for Medical Oncology ...

author_avatar
NASDAQ Market News